Lobbying registration dated 2026-02-16
Registrant: An Van Gerven
Client: Pfizer Canada ULC
Targeted institutions:
Atlantic Canada Opportunities Agency (ACOA)
Canadian Institutes of Health Research (CIHR)
Treasury Board Of Canada Secretariat (TBS)
Public Services and Procurement Canada (PSPC)
Indigenous Services Canada (ISC)
Global Affairs Canada (GAC)
Patented Medicine Prices Review Board (PMPRB)
Transport Canada (TC)
Intergovernmental Affairs Secretariat (IGA)
Justice Canada (JC)
Finance Canada (FIN)
House of Commons
National Defence (DND)
Employment and Social Development Canada (ESDC)
Veterans Affairs Canada (VAC)
Canada Revenue Agency (CRA)
Public Health Agency of Canada (PHAC)
Privy Council Office (PCO)
Senate of Canada
Health Canada (HC)
Prime Minister's Office (PMO)
Innovation, Science and Economic Development Canada (ISED)
Canada Border Services Agency (CBSA)
Canada Economic Development for Quebec Regions
Acts: Patent Act
Food and Drugs Act
Government funding received:
Lobbying activity details:
Monitoring and engaging on the Government’s national strategy for rare diseases; the Canadian Drug Agency; and the implementation of C64, An Act to Implement pharmacare.
Advocacy on the role of the Health Emergency Readiness Canada (HERC) Agency
Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages
Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.
Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
Advocacy on the Regulations Amending the Patent Rules and Certain Regulations Made Under the Patent Act which were published for consultation in Canada Gazette Part I (CGI) on May 18, 2024.1  Share concerns with Canada’s implementation of a patent term adjustment (PTA) system that is not compliant with its trade obligations, as it does not provide a meaningful remedy to patentees who are impacted by unreasonable patent office delays.
Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods
Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver and the World Health Organization pandemic treaty proposal
Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement
Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related new guidelines.
Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy
Discussions on the procurement of a COVID19 vaccine and therapy
Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.